Peter Ueda

Solna, AB, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 95 publications

Glucagon-like Peptide-1 Receptor Agonists and Risk for Anterior Ischemic Optic Neuropathy : A Nationwide Cohort Study.

Glucagon-like Peptide-1 Receptor Agonists and Risk for Anterior Ischemic Optic Neuropathy : A Nationwide Cohort Study.

Journal: Annals of internal medicine

Published: July 13, 2026

Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors Among Patients with Type 1 Diabetes: A Nationwide Register-Based Cohort Study.

Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors Among Patients with Type 1 Diabetes: A Nationwide Register-Based Cohort Study.

Journal: The Lancet regional health. Europe

Published: March 13, 2026

Ketoacidosis with SGLT2 inhibitors in routine clinical practice of type 2 diabetes: Scandinavian cohort and nested case-control study.

Ketoacidosis with SGLT2 inhibitors in routine clinical practice of type 2 diabetes: Scandinavian cohort and nested case-control study.

Journal: The lancet. Diabetes & endocrinology

Published: February 23, 2026

Use of Glucagon-Like Peptide-1 Receptor Agonists and Risk of Parkinson's Disease: Scandinavian Cohort Study.

Use of Glucagon-Like Peptide-1 Receptor Agonists and Risk of Parkinson's Disease: Scandinavian Cohort Study.

Journal: Diabetes, obesity & metabolism

Published: December 19, 2025

Improving 10-year cardiovascular risk prediction in patients with established cardiovascular disease: flexible addition of risk predictors on top of the SMART2 risk score.

Improving 10-year cardiovascular risk prediction in patients with established cardiovascular disease: flexible addition of risk predictors on top of the SMART2 risk score.

Journal: European journal of preventive cardiology

Published: October 12, 2025

Sexual Inactivity in Japan: A Scoping Review.

Sexual Inactivity in Japan: A Scoping Review.

Journal: Journal of sex research

Published: October 02, 2025

Prediction of incident heart failure in established atherosclerotic cardiovascular disease: the SMART2-HF model.

Prediction of incident heart failure in established atherosclerotic cardiovascular disease: the SMART2-HF model.

Journal: European heart journal

Published: September 12, 2025

Letter to the Editor from Hedberg et al: Treatment of Hypothyroidism That Contains Liothyronine Is Associated with Reduced Risk of Dementia and Mortality.

Letter to the Editor from Hedberg et al: Treatment of Hypothyroidism That Contains Liothyronine Is Associated with Reduced Risk of Dementia and Mortality.

Journal: The Journal of clinical endocrinology and metabolism

Published: September 08, 2025

Utilization and discontinuation of secondary prevention pharmacotherapy after myocardial infarction: a nationwide cohort study.

Utilization and discontinuation of secondary prevention pharmacotherapy after myocardial infarction: a nationwide cohort study.

Journal: European heart journal. Cardiovascular pharmacotherapy

Published: August 25, 2025

Predicting lifetime cardiovascular risk and benefits of preventive treatment in patients with established atherosclerotic cardiovascular disease: the SMART-REACH2 model.

Predicting lifetime cardiovascular risk and benefits of preventive treatment in patients with established atherosclerotic cardiovascular disease: the SMART-REACH2 model.

Journal: European heart journal

Published: July 15, 2025

Reply: Who Is the True High-Bleeding-Risk Patient?

Reply: Who Is the True High-Bleeding-Risk Patient?

Journal: JACC. Cardiovascular interventions

Published: March 20, 2025

GLP-1 receptor agonists and suicidality.

GLP-1 receptor agonists and suicidality.

Journal: BMJ (Clinical research ed.)

Published: February 26, 2025

Showing 1-12 of 95

Last Updated: 09/26/2026